EGFR and neoplasm: Our retrospective observations suggest that the PFS with initial EGFR-TKI treatment and the response rate to osimertinib might be promising predictors for osimertinib treatment in patients with EGFR-T790M-positive NSCLC; this may be due to the ratio of tumor heterogeneity that might be enriched during initial EGFR-TKI treatment.